**Indication**: Chronic lymphocytic leukaemia or small lymphocytic lymphoma

**INN**: Prednisolone

**Medicine type**: Chemical agent

**List type**: Complementary

**Formulations**: Oral > Solid: 5 mg; 25 mg

**EML status history**: First added in 2015 (TRS 994)  
Changed in 2021 (TRS 1035)

**Sex**: All

**Age**: Adolescents and adults

**Therapeutic alternatives**: prednisone (ATC codes: H02AB07)

**Patent information**: 
- Patents have expired in most jurisdictions
- Read more about patents.

**Tags**: Cancer

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended prednisone be specified as a therapeutic alternative under the square box listing for prednisolone on the EML and EMLc.